Suggested remit: To appraise the clinical and cost effectiveness of fruquintinib within its marketing authorisation for treating metastatic colorectal cancer.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6274

Provisional Schedule

Expected publication 18 September 2024

Project Team

Project lead Vonda Murray

Email enquiries

External Assessment Group Health Economics Research Unit and Health Services Research Unit, University of Aberdeen

Stakeholders

Companies sponsors Takeda (fruquintinib)
Others Department of Health and Social Care
  NHS England
Patient carer groups Black Health Agency for Equality
  Bladder and Bowel UK
  Bowel Cancer UK
  Cancer 52
  Cancer Black Care
  Cancer Equality
  Colostomy UK
  Crohn’s and Colitis UK
  Guts UK
  Helen Rollason Cancer Charity
  IA: Ileostomy and Internal Pouch Group
  Independent Cancer Patients Voice
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Pelican Cancer Foundation
  Red Trouser Day
  Sarcoma UK
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
  Together Support Group
Professional groups Association of Cancer Physicians
  Association of Coloproctology of Great Britain and Ireland
  Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland
  British Geriatrics Society
  British Institute of Radiology
  British Oncology Pharmacy Association
  British Psychosocial Oncology Society
  British Sarcoma Group
  British Society of Gastroenterology
  Cancer Research UK
  Primary Care Society for Gastroenterology
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Clinical Pharmacy Association
  UK Oncology Nursing Society
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies Bayer (regorafenib)
  Servier Laboratories (trifluridine-tipiracil)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Bowel Research UK
  Cochrane UK
  Cochrane Colorectal Group
  Foundation for Liver research
  Genomics England
  Institute of Cancer Research
  MRC Clinical Trials Unit
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
05 December 2023 Invitation to participate
10 October 2023 - 07 November 2023 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6274
15 June 2023 In progress. DHSC referral received
07 February 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
11 July 0024 Committee meeting: 1

For further information on our processes and methods, please see our CHTE processes and methods manual